In English | En español
Questions About Cancer? 1-800-4-CANCER

Clinical Trials Search Results

View Content for:
Display:
  •          
Help with display options.
Results 1-25 of 45 for your search:
Drug:  idarubicin
Find trials that include:  Any drugs shown
Trial Status:  Active
Start Over
        Show
1.

Phase: Phase IV
Type: Treatment
Status: Active
Age: Over 55
Sponsor: Other
Protocol IDs: GMALL02, NCT00198978
2.

Phase: Phase IV
Type: Treatment
Status: Active
Age: 15 to 65
Sponsor: Other
Protocol IDs: GMALL01, NCT00198991
3.

Phase: Phase IV
Type: Treatment
Status: Active
Age: Over 60
Sponsor: Other
Protocol IDs: AML-elderly 01/99 Trial, NCT00199147
4.

Phase: Phase IV
Type: Treatment
Status: Active
Age: 16 and over
Sponsor: Other
Protocol IDs: MK1-192, NCT00180128
5.

Phase: Phase IV
Type: Treatment
Status: Active
Age: 0 to 75
Sponsor: Other
Protocol IDs: LPA 2005, NCT00408278
6.

Phase: Phase IV
Type: Biomarker/Laboratory analysis, Treatment
Status: Active
Age: Any age
Sponsor: Other
Protocol IDs: PETHEMA-LAM07, NCT01041040
7.

Phase: Phase IV
Type: Treatment
Status: Active
Age: 55 and over
Sponsor: Other
Protocol IDs: LAL-07OLD, NCT01366898
8.

Phase: Phase IV
Type: Treatment
Status: Active
Age: 15 to 60
Sponsor: Other
Protocol IDs: LAL-AR/2011, NCT01540812
9.

Phase: Phase IV
Type: Treatment
Status: Active
Age: 15 to 60
Sponsor: Other
Protocol IDs: AML-01.10, NCT01587430
10.

Phase: Phase III, Phase II
Type: Biomarker/Laboratory analysis, Treatment
Status: Active
Age: 18 to 65
Sponsor: Other
Protocol IDs: MYFLAI07, NCT00909168
11.

Phase: Phase III
Type: Treatment
Status: Active
Age: 18 to 70
Sponsor: Other
Protocol IDs: APL0406, GIMEMA-SAL-APL0406, EUDRACT-2006-006188-22, GIMEMA-DSL-APL0406, EU-20725, NCT00482833
12.

Phase: Phase III
Type: Treatment
Status: Active
Age: 16 to 65
Sponsor: Other
Protocol IDs: NILG-AML 02/06, NCT00495287
13.

Phase: Phase III
Type: Treatment
Status: Active
Age: 6 months to 21 years
Sponsor: Other
Protocol IDs: CWS-2007-HR, 4033024 (BfArM), 293/2007AMG1 (Ethikkommission), 2007-001478-10, A2007/14 (Kinderkrebsstiftung), 498 (Krebsstudienregister), NCT00876031
14.

Phase: Phase III
Type: Treatment
Status: Active
Age: 1 to 18
Sponsor: Other
Protocol IDs: CCLG-ALLR3, CCLG-ALLR3, ISCRTN-45724312, EUDRACT-2004-000052-16, EU-20938, NCT00967057
15.

Phase: Phase III
Type: Treatment
Status: Active
Age: 18 and over
Sponsor: Other
Protocol IDs: AMLSG 09-09, NCT00893399
16.

Phase: Phase III
Type: Treatment
Status: Active
Age: 18 and over
Sponsor: Other
Protocol IDs: C-022, NCT01145846
17.

Phase: Phase III
Type: Treatment
Status: Active
Age: 18 to 60
Sponsor: Other
Protocol IDs: AML 2002 #061, NCT01414231
18.

Phase: Phase III
Type: Treatment
Status: Active
Age: 7 to 60
Sponsor: Other
Protocol IDs: MST-AML-307PLAH-ASH, NCT01484171
19.

Phase: Phase II, Phase I
Type: Treatment
Status: Active
Age: 18 to 60
Sponsor: Other
Protocol IDs: EORTC-06061, EU-20905, 2006-004912-28, GIMEMA-AML-14A, EudraCT-2006-004912-28, NCT00838240
20.

Phase: Phase II, Phase I
Type: Treatment
Status: Active
Age: 65 and over
Sponsor: Other
Protocol IDs: PANOBIDARA, NCT00840346
21.

Phase: Phase II, Phase I
Type: Treatment
Status: Active
Age: 18 and over
Sponsor: Other
Protocol IDs: 2010-0788, NCT01289457
22.

Phase: Phase II, Phase I
Type: Treatment
Status: Approved-not yet active
Age: 18 to 65
Sponsor: Other
Protocol IDs: PLERIFLAG, NCT01435343
23.

Phase: Phase II, Phase I
Type: Treatment
Status: Active
Age: 20 to 65
Sponsor: Other
Protocol IDs: AML-2011-01, NCT01518556
24.

Phase: Phase II, Phase I
Type: Biomarker/Laboratory analysis, Treatment
Status: Active
Age: 18 and over
Sponsor: Other, Pharmaceutical / Industry
Protocol IDs: KS-2009-003, 2010-021719-18, NCT01534702
25.

Phase: Phase II
Type: Treatment
Status: Active
Age: 18 and over
Sponsor: Other
Protocol IDs: T-CID, NCT00124813
1   
New Search